Department of Health

Website of the Department of Health

Please note that this website has a UK government access keys system.

You are here:

National Institute for Health and Clinical Excellence (NICE): 14th work programme technology appraisals

  • Author:
    Department of Health
  • Published date:
    19 June 2007
  • Gateway reference:
    8476
  • Copyright holder:
    Crown

Department of Health Ministers have carefully considered all the representations received during consultation and have decided the following technology appraisals should be added to NICE’s work programme:

Single technology appraisals

  • Bevacizumab (Avastin) for breast cancer. 
    To appraise the clinical and cost-effectiveness of bevacizumab in combination with paclitaxel for the treatment of advanced or metastatic breast cancer.
  • Telbivudine (ldt) for the treatment of chronic hepatitis B
    To appraise the clinical and cost-effectiveness of telbivudine for chronic hepatitis B
  • Entecavir (Baraclude) for the treatment of chronic hepatitis B
    To appraise the clinical and cost-effectiveness of entecavir for chronic hepatitis B
  • Tolevamer (GT 267-004; Genzyme) for the treatment of clostridium difficile associated disease
    To appraise the clinical and cost-effectiveness of tolevamer for Clostridium difficile associated disease.
  • Febuxostat (TMX 67, TEI 6720; Ipsen) for the management of hyperuricaemia in patients with gout
    To appraise the clinical and cost-effectiveness of febuxostat for the management of hyperuricaemia in adults with gout.
  • Tocilizumab (Actemra) for the treatment of juvenile idiopathic arthritis.
    To appraise the clinical and cost-effectiveness of tocilizumab for juvenile idiopathic arthritis.
  • Adalimumab (Humira) for moderate to severe chronic plaque psoriasis
    To appraise the clinical and cost-effectiveness of adalimumab within its licensed indication for psoriasis.

Multiple technology appraisals

  • Bezacizumab (Avastin), Sorafenib tosylate (Nexavar) and Sunitinib (Sutent) for renal cell carcinoma – referred in June 2007
  • Following consultation on the remit, Ministers agreed the appraisal should be extended to include temsirolimus.  The revised remit was referred to NICE in September 2007:
  • Bezacizumab (Avastin), Sorafenib tosylate (Nexavar), Sunitinib (Sutent) and Temsirolimus (Torisel) for renal cell carcinoma
    To appraise the clinical and cost-effectiveness of bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma.

Additional links

Ordering publications

Contact details for obtaining hard-copy DH publications.

Help viewing PDFs

Help viewing PDFs

Useful tips to ensure you get the most from PDFs and the free Reader program. Topics covered include accessibility, troubleshooting and searching files.

Additional Links

Access keys